Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
Status:
Recruiting
Trial end date:
2024-12-03
Target enrollment:
Participant gender:
Summary
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower
dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or
refractory MM. The overall response rate was 71% including complete remission of 15%. Median
progression free survival and overall survival were 8.9 and 30.5 months. In addition, grade
3-4 toxicities such as neutropenia, and infections were reduced. This study supported that
lower dose lenalidomide may be optimal stating dose for elderly patients with frailty.